1 2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseases. WHO Press, 2008. https://www.who.int/nmh/publications/9789241597418/en/ [accessed 2020-2-22].
2 Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet. 2012; 379: 1269–71.
3 Ikeda N, Inoue M, Iso H, Ikeda S, Satoh T, Noda M, et al. Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan: a comparative risk assessment. PLoS Med. 2012; 9: e1001160.
4 Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, David Hammond BF, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013; 108: 193–202.
5 Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Vol. 2013, Cochrane Database Syst Rev. 2013: CD009329.
6 Soria R, Legido A, Escolano C, Yeste AL, Montoya J. A randomised controlled trial of motivational interviewing for smoking cessation. Br J Gen Pract. 2006; 56(531): 768– 74.
7 JCS Joint Working Group; Japanese Society for Oral Health; Japanese Society of Oral and Maxillofacial Surgeons; Japanese Society of Public Health; Japanese Respiratory Society; Japan Society of Obstetrics and Gynecology et al. Guidelines for Smoking Cessation (JCS 2010)--digest version. Circ J. 2012; 76: 1024–43.
8 Gwaltney CJ, Metrik J, Shiffman S. Self-efficacy and smoking cessation: a meta- analysis. Psychol Addict Behav. 2013; 23(1): 1–20.
9 Chie T, Hideo T, Aki I, Syoko A, Mihoko S, Ayumi K et al. Factors associated with 4- weeks quit rate before the end of smoking cessation therapy in Japan. Japanese Journal of Tobacco Control. 2011; 6(3): 34–40.
10 Marino MG, Fusconi E, Magnatta R, Panà A, Maurici M. Epidemiologic determinants affecting cigarette smoking cessation: A retrospective study in a national health system (SSN) treatment service in Rome (Italy). J Environ Public Health. 2010; 2010: 183206. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853854/ [accessed 2020-2-22]
11 Howie JG, Heaney DJ, Maxwell M. Measuring quality in general practice. Pilot study of a needs, process and outcome measure. Occas Pap R Coll Gen Pract. 1997; (75):i– xii, 1–32.
12 Howie JG, Heaney DJ, Maxwell M, Walker JJ, Freeman GK, Rai H. Quality at general practice consultations: cross sectional survey. BMJ. 1999; 319(7212): 738–43.
13 Howie JG, Heaney DJ, Maxwell M, Walker JJ. A comparison of a Patient Enablement Instrument (PEI) against two established satisfaction scales as an outcome measure of primary care consultations. Fam Pract. 1998; 15(2): 165–71.
14 Kurosawa S, Matsushima M, Fujinuma Y, Hayashi D, Noro I, Kanaya T, et al. Two principal components, coping and independence, comprise patient enablement in Japan: cross sectional study in Tohoku area. Tohoku J Exp Med. 2012; 227(2): 97– 104.
15 Kawakami N, Takatsuka N, Inaba S. Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav. 1999; 24(2): 155–66.
16 Japanese Society of Circulation, The Japan Lung Cancer Society, Japan Cancer Association, et al. 6th manual of anti-smoking therapy in Japan, 2014. In Japanese. http://www.j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev6.pdf [accessed 2020-2-22].
17 The Health Consequences of Smoking: A Report of the Surgeon General U.S. Department of Health and Human Services National Library of Medicine 2004 vol: 2012. Office of the Surgeon General (US), Office on Smoking and Health (US) Atlanta (GA): Centers for Disease Control and Prevention (US); 2004. https://www.ncbi.nlm.nih.gov/books/NBK44695/pdf/Bookshelf_NBK44695.pdf [accessed 2020-2-22].
18 Haughney J, Cotton P, Rosen J, Morrison K, Price D. The use of a modification of the Patient Enablement Instrument in asthma. Prim Care Respir J. 2007 Apr; 16(2): 89–92.
19 Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978; 3(3–4): 235–41.
20 Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9): 1119–27.
21 Cohen J. Statistical Power Analysis for the Behavioral Sciences Second Edition. New York: Lawrence Erlbaum Associates, Publishers 1998: 19–74.
22 StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
23 StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.
24 Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49(12): 1373–9.
25 Mafalda R, Pedro MT, Irene L, Luís S, Jaime CS. The Modified Patient Enablement Instrument: A Portuguese Cross-Cultural Adaptation, Validity and Reliability Study. NPJ Prim Care Respir Med. 2017 Jan 12; 27: 16087.
26 Ministry of Health, Labour and Welfare Central Social Insurance Medical Council General Meeting: Special Survey on Verification of Results of Reimbursement for Medical Care. A survey report on the success rate of smoking cessation in medical institutions that calculate nicotine dependence management fees (2009 Survey) in Japanese. https://www.mhlw.go.jp/shingi/2010/06/dl/s0602-3i.pdf [accessed 2020-2- 22].
27 Hsueh Y. The Hawthorne experiments and the introduction of Jean Piaget in American industrial psychology, 1929–1932. Hist Psychol. 2002; 5(2): 163–89.
28 Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007; 9(3): 315–27.
論文の公開元へ
